Treatment of Open-Angle Glaucoma with iStent Implantation Combined with Phacoemulsification in Polish Caucasian Population

Figures & data

Table 1 Characteristics of the Patients

Characteristics	n	Level
N	78	100.0%
Sex, n (%)
Women	53	67.9%
Men	25	32.1%
Age, years, mean (SD)	77	72.48 (8.70)
Glaucoma, n (%)
JPOK	63	80.8%
PEX	15	19.2%
Follow-up time, months	77
Median (Q1;Q3)		24.00 (19.00;24.00)
Mean (SD)		21.91 (5.16)
Number of drugs, median (Q1;Q3)	77	2.00 (1.00;4.00)
Number of drugs, n (%)
0	2	2.6%
1	35	45.5%
2	24	31.2%
3	11	14.3%
4	3	3.9%
5	2	2.6%
VA baseline	78
Median (Q1;Q3)		0.50 (0.34;0.68)
Mean (SD)		0.56 (0.56)
IOP preop	78
Median (Q1;Q3)		18.00 (16.00;24.00)
Mean (SD)		18.44 (3.50)

Abbreviations: n, sample size; SD, standard deviation; JPOK, jaskrę pierwotną otwartego kąta (open angle glaucoma); PEX, pseudoexfoliation glaucoma; Q1, quartile 1; Q3, quartile 3; VA, visual acuity; IOP, intraocular pressure.

Table 2 Change of Intraocular Pressure (IOP), Visual Acuity (VA) and Number of Medications After 12 Months and 24 Months of Observation

Time	n	Mean (SD)	Median (Range)	MD (95% CI)	p
IOP
Pre-op	78	18.44 ±3.50	18.00 (16.00,24.00)
12th month	64	16.06±2.62	16.00 (11.00,27.00)	−5.88 (−6.51, −4.70)	<0.001
24th month	76	15.71±2.69	16.00 (10.50,23.00)	−6.23 (−7.11, −5.37)	<0.001
VA
Pre-op	78	0.56±0.56	0.50 (0.01,5.00)
12th month	64	0.91±0.17	1.00 (0.20,1.00)	0.35 (0.18, 0.48)	<0.001
24th month	75	0.90±0.19	1.00 (0.10,1.00)	0.34 (0.21, 0.48)	<0.001
Drugs
Pre-op	77	1.79±1.03	2.00 (0.00,4.00)
12th month	63	0.46±0.84	0.00 (0.00,3.00)	−2.00 (−2.50, −1.00)	<0.001
24th month	50	0.52±0.95	0.00 (0.00,4.00)	−2.00 (−2.50, −1.00)	<0.001

Notes: MD – mean (for IOP, VA) or median (for drugs) difference calculated as 12th month minus pre-op or 24th month minus pre-op with 95% confidence interval. Time periods compared with paired t-test (IOP, VA) or Wilcoxon rank sum test (drugs).

Abbreviations: IOP, intraocular pressure; VA, visual acuity; SD, standard deviation; MD, mean deviation.

Table 3 Change of Intraocular Pressure (IOP) After 12 Months and 24 Months of Observation

Period of Change	n	IOP Change (mmHg)		IOP Change (%)
		Mean (SD)	Median (Range)	Mean (SD)	Median (Range)
12th month vs baseline	64	−2.33 ± 3.81	−2,55 (−16.00;10.00)	−10.65 ± 19.68	−13.03 (−55.17,58.82)
24th month vs baseline	76	−2.70 ± 4.18	−2,50 (−16.90,8.00)	−12.06 ± 21.15	−12.77 (−55.17,72.73)

Abbreviations: IOP, intraocular pressure; SD, standard deviation.

Table 4 The Amount of Intraocular Pressure (IOP) Lowering Medications Surgery and 24 Months Post-Op

Number of Drugs, n (%)	Pre-Operatively, n (%)		Post-Operatively, n (%)		p value
0	2	(2.6)	53	(68)	0.001
1	35	(45.5)	13	(18)	0.030
2	24	(31.2)	10	(12)	0.020
3	11	(14.3)	2	(2.5)	0.040
4	5	(6.5)	0	0	0.001

Figure 1 Kaplan–Meier cumulative incidence of effective treatment and complete success. Dotted lines indicate 95% confidence interval. Complete success was defined as an intraocular pressure (IOP) <15 mmHg without drugs, the effective treatment success was defined as IOP < 15 mmHg with or without drugs.